National Institute on Drug Abuse, Division of Intramural Research, PO Box 5180, Baltimore, MD 21224-0180

B -- PROFILING SCREEN, 9 COMPOUNDS SOL 98-nida/irp/1006-TA DUE 092598 POC Tonya D. Anderson 410-550-1527 Fax 410-550-3146 The procurement involves a broad characterization of the competition of nine newly synthesized drugs for various receptor sites using radioisotopes as labels and follow-up functional assays for compounds showing activity at particular sites. This screen, as it's name implies, consists of a panel of panel of primary and secondary functional assays designed to profile the activity of compounds against a broad panel of known physiologically important mammalian receptors. Samples are to be screened at 31 molecular targets with invivo or in vitro follow-up testing when compounds are active in primary tests. Samples are to be screened at 31 molecular targets with in vivo or in intro follow-up testing when compounds are active in primary tests. Samples must be first screened in duplicate in each primary assay at a concentration of 10 um in each of this binding assays. If inhibition or enhancement of greater tha 50% is observed, the test must be repeated in duplicate at the original concentration and at 10-fold, 100-fold, and 1000-fold lower concentration. Samples with confirmed activity must be evaluated in secondary biological response tests to determine agonist or antagonist effects, and their minimal inhibitory concentrations or minimal effective doses. Concurrent vehicle and reference standards must be conducted with each assay. Primary sites to be targeted will be given. You may fax your request for solicitation to 410-550-3146. This a small business set-a-side procurement. This will be awarded under simplified acquisition procedures. Posted 08/21/98 (W-SN240296). (0233)

Loren Data Corp. http://www.ld.com (SYN# 0010 19980825\B-0003.SOL)